Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Repository Corticotropin Injection Clear all
Terminated Phase 2Phase 3 Interventional Results available

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

NCT03068754
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Acthar, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 5:44 AM EDT
Withdrawn Phase 2 Interventional

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
repository corticotropin injection, Saline
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

NCT03287635
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Corticotropin 80Unit/Ml Repository Injection
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 21, 2026, 5:44 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

NCT00947895
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylprednisolone, ACTH, IV placebo, IM placebo
Drug · Other
Lead sponsor
Neurologique Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ponte Vedra, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 21, 2026, 5:44 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

NCT02486744
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Acthar Gel
Drug
Lead sponsor
Youngstown State University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 21, 2026, 5:44 AM EDT
Not listed Phase 4 Interventional

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

NCT01939132
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Open label H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT03727776
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 21, 2026, 5:44 AM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

ACTH for Fatigue in Multiple Sclerosis Patients

NCT02315872
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTH, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Acthar Gel in Participants With Pulmonary Sarcoidosis

NCT03320070
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 21, 2026, 5:44 AM EDT
Withdrawn Phase 4 Interventional

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

NCT03398018
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
repository corticotropin injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 21, 2026, 5:44 AM EDT
Terminated Phase 4 Interventional Results available

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 21, 2026, 5:44 AM EDT
Withdrawn Phase 4 Interventional

ACTHAR Therapy for Central Nervous System Sarcoidosis

NCT02920710
View directory record Official record
Conditions
Sarcoidosis
Interventions
Repository Corticotropin Injection
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 21, 2026, 5:44 AM EDT
Not listed Phase 4 Interventional

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
Iraj Sabahi Research Inc.
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pleasanton, California • Turlock, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 21, 2026, 5:44 AM EDT
Not listed Not applicable Interventional

Comprehensive Analysis of Relapse in Multiple Sclerosis

NCT01906684
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Tanner Foundation for Multiple Sclerosis
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

NCT01966718
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Repository corticotropin injection
Drug
Lead sponsor
Arthritis Treatment Center, Maryland
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations

NCT01888354
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
H.P. Acthar Gel (repository corticotropin injection)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oceanside, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

NCT01769937
View directory record Official record
Conditions
Lupus Erythematosus Systemic Exacerbation
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

NCT01987167
View directory record Official record
Conditions
Optic Neuritis
Interventions
ACTHAR
Drug
Lead sponsor
Neuro-Ophthalmologic Associates, PC
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177
View directory record Official record
Conditions
Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions
Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 21, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Adrenocorticotropic Hormone in Membranous Nephropathy

NCT03025828
View directory record Official record
Conditions
Membranous Nephropathy
Interventions
ACTHar
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 21, 2026, 5:44 AM EDT